Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

The blood–brain barrier (BBB), a unique structure in the central nervous system (CNS),
protects the brain from bloodborne pathogens by its excellent barrier properties …

Breast tumors generally consist of a diverse population of cells with varying gene expression
profiles. Breast tumor heterogeneity is a major factor contributing to drug resistance …

Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their
design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were …

Antibody–drug conjugates (ADCs) are being actively pursued as a treatment option for
cancer following the regulatory approval of brentuximab vedotin (Adcetris) and ado …

The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer
has propelled the development of HER-targeting monoclonal antibodies (mAb) such as …

Valine–citrulline linkers are commonly used as enzymatically cleavable linkers for antibody–
drug conjugates. While stable in human plasma, these linkers are unstable in mouse plasma …